Peng LF, Schaefer EAK, Maloof N, et al. Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. J Infect Dis. 2011;204(4):609-16. doi:10.1093/infdis/jir303.
Peng LF, Kim SS, Matchacheep S, et al. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob Agents Chemother. 2007;51(10):3756-9. doi:10.1128/AAC.00233-07.
Kim SS, Peng LF, Lin W, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132(1):311-20. doi:10.1053/j.gastro.2006.10.032.
Moore JP, Simpson G, McKeating JA, Burakoff SJ, Schreiber SL, Weiss RA. CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro. Virology. 1992;188(2):537-44.
Finberg RW, Diamond DC, Mitchell DB, et al. Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120. Science. 1990;249(4966):287-91.
Kang M-S, Lee EK, Soni V, et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J Virol. 2011;85(6):2859-68. doi:10.1128/JVI.01628-10.
Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48(6):1769-78. doi:10.1002/hep.22549.